Chairman, President & CEO, Abbott Laboratories
Search every verified Robert Ford interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On Abbott's first-quarter 2026 earnings call, Robert Ford stated he remains "very confident" in an acceleration of growth in the second half of the year, saying the company knows "what the drivers are" and is "laser focused" on execution. Ford described the integration of Exact Sciences as going "very well" and expressed optimism about the continuous glucose monitoring (CGM) market, estimating that 70 to 80 million people globally should be using CGMs compared to a current market of around 10 to 12 million. He also said he expects proposed language for CMS type 2 non-insulin coverage "coming soon," which he said would add coverage for close to 10 million people. Regarding Abbott's nutrition business, Ford said he would not make a long-term strategic decision based on near-term challenges and that his focus is on returning the business to its prior growth rate. He described the company as "very diversified" and noted that while it would be "great" for every business to beat expectations, that does not always happen. Ford also said the electrophysiology market is expected to grow in the "mid to high teens" and that Abbott is "shooting to do better than that."
“I'm very bullish on this market. If I look at the big picture here, I'm very bullish on the CGM market as you know, Larry, I've always been and I continue to be. If I look at our assessment of the amount of people that should be on a CGM on a global basis, we estimate between 70 to 80 million people on CGMs should be....”
“I expect proposed language of that coming soon. I can't tell you the exact month, Larry, and I'm not going to try and forecast what it is, when it is, but I know it's going to happen. And I know that it's going to add close to 10 million people that don't have coverage now that now will be able to have coverage. And ob...”
“I think ultimately, you know, the way our business is, we're very diversified company. We lay out all of the different businesses. We break out even within sectors, we break them out and be able to show the performance in that. My view here is that yeah, it would be great to have every single business beating all of th...”
“I never going to make a long-term strategic decision based on kind of near-term challenges. Obviously nutrition's going through some near-term challenges and going through some transition and recovery phase and that's what my focus is on is getting our business back to a growth rate that we had seen over the last kind...”
04/16/2026 Q&A: 13:48 Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Meniere…
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
The Boston College Chief Executives Club welcomed Robert B. Ford, the Chairman & CEO of Abbott, to engage in a fireside chat ...
Abbott CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk lessons learned from the pandemic, quarterly earnings, weight loss drugs and more.
Robert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on L…
#COVID19testing #Abbottpresident #coronavirustesting On this episode of Yahoo Finance Presents, Abbott President & CEO Robert Ford, sat down with Yahoo Finance's Anjalee Khemlani to discuss Abbott's upcoming keynote address at CES 2022 and COVID-19 test pricing and supply chain challenges. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: • Elizabeth Holmes: 'Valley of Hype' [pre-sh... Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: • Video Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Fin…
Full video : • BC CEO Club: A Conversation w Robert Ford,... Abbot [a Catholic Monk/Father] Laboratories makes the fraudulent Covid PCR tests!
Warren K. Zola, executive director of the Boston College Chief Executives Club, speaks with Robert Ford, president & CEO of Abbott. Held on March 8, 2021, this "Conversation with a CEO" touches upon a variety of subjects including Abbott's role in developing rapid COVID in-home tests, how they are leading the way on connected health care to get closer to the patient and deliver results, what post-pandemic diagnostics will look like and their high school internship program geared towards engaging young women to explore STEM careers.
Sign in to search the full transcript archive, filter by topic, and access every quote from Robert Ford.